Compare · NVS vs TRAX
NVS vs TRAX
Side-by-side comparison of Novartis AG (NVS) and First Tracks Biotherapeutics Inc. (TRAX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and TRAX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $284.18B, about 444.6x TRAX ($639.2M).
- TRAX has been more active in the news (14 items in the past 4 weeks vs 1 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 8 for TRAX).
- Company
- Novartis AG
- First Tracks Biotherapeutics Inc.
- Price
- -
- -
- Market cap
- $284.18B
- $639.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 1
- 14
- Recent ratings
- 25
- 8
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
Latest TRAX
- First Tracks Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Director Schmid John P. converted options into 6,030 shares, increasing direct ownership by 19% to 37,652 units (SEC Form 4)
- Director Marquet Magda converted options into 6,030 shares, increasing direct ownership by 61% to 15,960 units (SEC Form 4)
- Director Jain Rita converted options into 7,330 shares, increasing direct ownership by 62% to 19,194 units (SEC Form 4)
- Director Orwin John A converted options into 6,030 shares, increasing direct ownership by 57% to 16,695 units (SEC Form 4)
- Director Ware J. Anthony converted options into 6,030 shares, increasing direct ownership by 63% to 15,660 units (SEC Form 4)
- Director Fenton Dennis M converted options into 6,030 shares, increasing direct ownership by 121% to 10,995 units (SEC Form 4)
- Amendment: SEC Form 4 filed by Director Fenton Dennis M
- Amendment: SEC Form 4 filed by Director Jain Rita
- Amendment: SEC Form 4 filed by Director Marquet Magda